研发人员降超三成 “基因编辑第一股”今日申购丨打新早知道

Core Viewpoint - The company, BaiAo SaiTu, is launching an IPO on the Sci-Tech Innovation Board, focusing on gene editing and related services, despite a significant reduction in R&D personnel. Group 1: Company Overview - BaiAo SaiTu is recognized as the "first stock in gene editing" and was listed on the Hong Kong Stock Exchange in 2022 [2] - The company operates four technical platforms: gene-edited model animals, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [2] - As of June 30, 2025, BaiAo SaiTu has completed approximately 5,300 customized gene editing projects and developed over 4,300 gene-edited animal and cell line models [2] Group 2: R&D and Personnel Changes - The number of R&D personnel at BaiAo SaiTu decreased from 627 at the end of 2022 to 403 by mid-2025, a reduction of over 30% [3] - The company stated that the large-scale R&D phase concluded in Q3 2023, leading to a significant drop in internal R&D projects and subsequent personnel optimization [3] Group 3: Business Performance - BaiAo SaiTu's business segments include preclinical pharmacology and efficacy evaluation, model animal sales, antibody development, and gene editing services [3] - Model animal sales have become increasingly significant, generating revenue of 274 million yuan in the first half of the year, accounting for 44.2% of total revenue [3] - The largest client, Gilead Sciences, Inc., contributed 88 million yuan in revenue during the first half of the year, representing 14.25% of total revenue [3]